CorMedix Inc (CRMD) concluded trading on Wednesday at a closing price of $10.05, with 4.36 million shares of worth about $43.85 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 82.07% during that period and on October 30, 2024 the price saw a loss of about -22.51%. Currently the company’s common shares owned by public are about 57.76M shares, out of which, 56.86M shares are available for trading.
Stock saw a price change of -18.62% in past 5 days and over the past one month there was a price change of 24.07%. Year-to-date (YTD), CRMD shares are showing a performance of 167.29% which increased to 215.05% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.57 but also hit the highest price of $13.85 during that period. The average intraday trading volume for CorMedix Inc shares is 1.00 million. The stock is currently trading -6.78% below its 20-day simple moving average (SMA20), while that difference is up 20.52% for SMA50 and it goes to 87.05% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CorMedix Inc (NASDAQ: CRMD) currently have 57.76M outstanding shares and institutions hold larger chunk of about 29.59% of that.
The stock has a current market capitalization of $580.50M and its 3Y-monthly beta is at 1.62. It has posted earnings per share of -$0.93 in the same period. It has Quick Ratio of 4.43 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRMD, volatility over the week remained 11.70% while standing at 6.84% over the month.
Stock’s fiscal year EPS is expected to rise by 45.05% while it is estimated to increase by 171.60% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Rodman & Renshaw on August 26, 2024 offering a Buy rating for the stock and assigned a target price of $13 to it. Coverage by RBC Capital Mkts stated CorMedix Inc (CRMD) stock as an Outperform in their note to investors on August 10, 2023, suggesting a price target of $6 for the stock. On February 17, 2021, Needham Initiated their recommendations, while on September 29, 2020, JMP Securities Initiated their ratings for the stock with a price target of $22. Stock get a Buy rating from Truist on September 21, 2020.
